Key Insights

Highlights

Success Rate

100% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 30/100

Termination Rate

0.0%

0 terminated out of 16 trials

Success Rate

100.0%

+13.5% vs benchmark

Late-Stage Pipeline

44%

7 trials in Phase 3/4

Results Transparency

0%

0 of 8 completed with results

Key Signals

100% success

Data Visualizations

Phase Distribution

15Total
Not Applicable (1)
P 1 (2)
P 2 (5)
P 3 (7)

Trial Status

Completed8
Recruiting5
Active Not Recruiting3

Trial Success Rate

100.0%

Benchmark: 86.5%

Based on 8 completed trials

Clinical Trials (16)

Showing 16 of 16 trials
NCT06862791Phase 2Active Not RecruitingPrimary

A Weight Loss Study Evaluating Subcutaneous Treatment With AZD9550 and AZD6234 in Combination Against Placebo or Each of the Drugs Alone

NCT07351045Phase 3RecruitingPrimary

A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes

NCT07351058Phase 3RecruitingPrimary

A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes

NCT06937099Phase 3Recruiting

Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight

NCT06937086Phase 3Recruiting

Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study

NCT07081958Phase 2Active Not RecruitingPrimary

A Study Evaluating the Effect of Daily Oral RO7795081 in Participants With Obesity or Overweight With at Least One Weight-Related Comorbidity

NCT05813925Phase 3CompletedPrimary

A Research Study to See How Well CagriSema Helps People in East Asia With Excess Body Weight Lose Weight

NCT05996848Phase 3CompletedPrimary

A Research Study to See How Well CagriSema Helps People in China With Excess Body Weight Lose Weight

NCT06988553Phase 1CompletedPrimary

A Phase Ib Study of AZD5004 in Chinese Participants With Overweight/Obesity With or Without Type 2 Diabetes Mellitus

NCT06579092Phase 2CompletedPrimary

Effects of AZD5004 in Adults Who Are Living With Obesity or Overweight With at Least 1 Weight-related Comorbidity

NCT06595238Phase 2CompletedPrimary

A Study in Participants With Obesity or Overweight With at Least One Weight-related Comorbidity

NCT07128888Phase 1RecruitingPrimary

Study on Gastric Emptying Effect and Drug-Drug Interactions of GZR18 Injection

NCT06867718Phase 2Active Not RecruitingPrimary

Study of Once-Daily Oral RGT001-075 Compared With Placebo in Adults With Obesity or Are Overweight With Weight-Related Health Conditions

NCT05607680Phase 3CompletedPrimary

A Study of IBI362 in Participants With Obesity or Overweight

NCT05153590CompletedPrimary

A Research Study About Weight Loss and Treatment Patterns With the Use of Saxenda® in Adults in Real-life Settings in Switzerland

NCT03629301Not ApplicableCompletedPrimary

Obesity Treatment Using an Internet-delivered Intervention Based on the Diabetes Prevention Program in Mexican Adults

Showing all 16 trials

Research Network

Activity Timeline